Urol. praxi. 2022;23(2):80-84 | DOI: 10.36290/uro.2022.017

The role of thermoablative methods in the treatment of renal tumors

MUDr. Vlastimil Válek jr., prof. MUDr. Vlastimil Válek, CSc., MBA, EBIR, doc. MUDr. Marek Mechl, Ph.D., MBA
Klinika radiologie a nukleární medicíny, LF MU a FN Brno

Percutaneous thermoablation is an alternative method of treatment for localized renal tumors (T1a). Its application is mainly in elderly polymorbid patients who are not candidates for surgery. The postoperative outcome in terms of overall survival at 1 year is similar in patients after thermoablation and resection. Overall survival at longer interval is better in the resection group compared with the thermoablation group. Surgical management of this group of tumors remains the method of choice.

Keywords: RFA, MWA, cryoablation, resection.

Received: March 7, 2022; Revised: March 29, 2022; Accepted: March 29, 2022; Prepublished online: March 29, 2022; Published: June 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Válek V, Válek EBIR V, Mechl M. The role of thermoablative methods in the treatment of renal tumors. Urol. praxi. 2022;23(2):80-84. doi: 10.36290/uro.2022.017.

Download citation

References

  1. Elexa P, Král J, Pavlovský M, et al. Případ pacientky s bilaterálními tumory ledvin s nutností jednostranné nefrektomie z vitální indikace. Urol. praxi. 2015;16(5):222-5.
  2. Ladman J, Handrejch L, Šafařík L, et al. Bilaterální synchronní renální karcinom s odlišným histologickým nálezem. Urol. praxi. 2016;17(2):87-90. Go to original source...
  3. Liu N, Huang D, Cheng X, Chong Y, et al. Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long­‑term oncologic outcomes in both clear cell and non­‑clear cell of the most common subtype. Urologic Oncology: Seminars and Original Investigations. 2017;35(8):530.e1-530.e6. Go to original source... Go to PubMed...
  4. Žemla P, Vidlář A, Šantavý P. Karcinom ledviny s nádorovým trombem do pravé srdeční síně. Urol. praxi. 2018;19(3):142-4. Go to original source...
  5. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow­‑up††Approved by the ESMO Guidelines Committee: September 2008, last update January 2019. This publication supersedes the previously published version - Ann Oncol 2016; 27 (Suppl 5): v58-v68. Annals of Oncology. 2019;30(5):706-20. Go to original source... Go to PubMed...
  6. Hoffmann P, Dvořák P, Navrátil P, et al. Percutaneous radiofrequency ablation of the renal tumors - five years experience with minimally invasive therapy. Ces Radiol. 2011;65(2):124-30.
  7. Shakeri S, Raman SS. Trends in Percutaneous Thermal Ablation Therapies in the Treatment of T1a Renal Cell Carcinomas Rather than Partial Nephrectomy/Radical Nephrectomy. Semin Intervent Radiol. 2019;36(3):183-93. Go to original source... Go to PubMed...
  8. Knavel EM, Brace CL. Tumor Ablation: Common Modalities and General Practices. Tech Vasc Interv Radiol. 2013;16(4): 192-200. Go to original source... Go to PubMed...
  9. Chung MSTM, Maxwell AW, Wang L­‑J, Mayo­‑Smith WW, Dupuy DE. Should Renal Mass Biopsy Be Performed prior to or Concomitantly with Thermal Ablation? Journal of Vascular and Interventional Radiology. 2018;29(9):1240-4. Go to original source... Go to PubMed...
  10. Widdershoven CV, Aarts BM, Zondervan PJ, et al. Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow­‑up. Abdom Radiol (NY). 2021;46(1):373-9.
  11. Park BK, Shen S­‑H, Fujimori M, Wang Y. Thermal Ablation for Renal Cell Carcinoma: Expert Consensus from the Asian Conference on Tumor Ablation. Korean Journal of Radiology. 2021;22(9):1490-6. Go to original source... Go to PubMed...
  12. Shakeri S, Raman SS. Percutaneous Thermal Ablation for Treatment of T1a Renal Cell Carcinomas. Radiologic Clinics. 2020;58(5):981-93. Go to original source... Go to PubMed...
  13. Marshall HR, Shakeri S, Hosseiny M, et al. Long­‑Term Survival after Percutaneous Radiofrequency Ablation of Pathologically Proven Renal Cell Carcinoma in 100 Patients. Journal of Vascular and Interventional Radiology. 2020;31(1):15-24. Go to original source... Go to PubMed...
  14. Gunn AJ, Parikh NS, Bhatia S. Society of Interventional Radiology Quality Improvement Standards on Percutaneous Ablation in Renal Cell Carcinoma. Journal of Vascular and Interventional Radiology. 2020;31(2):195-201.e3. Go to original source... Go to PubMed...
  15. Staněk R. Použití tkáňového lepidla při ledvinu šetřící parciální nefrektomii. Urol. praxi. 2010;11(6):335-7.
  16. Shi L, He Y, Liu C, Qian X, Wang Z. Local ablation vs partial nephrectomy in T1N0M0 renal cell carcinoma: An inverse probability of treatment weighting analysis. Cancer Med. 2020;9(21):7988-8003. Go to original source... Go to PubMed...
  17. Yu J, Zhang X, Liu H, et al. Percutaneous Microwave Ablation versus Laparoscopic Partial Nephrectomy for cT1a Renal Cell Carcinoma: A Propensity­‑matched Cohort Study of 1955 Patients. Radiology. 2020;294(3):698-706. Go to original source... Go to PubMed...
  18. Yu J, Liang P, Yu X, Cheng Z, et al. US­‑guided Percutaneous Microwave Ablation versus Open Radical Nephrectomy for Small Renal Cell Carcinoma: Intermediate­‑term Results. Radiology. 2014;270(3):880-7. Go to original source... Go to PubMed...
  19. Uhlig J, Kokabi N, Xing M, Kim HS. Ablation versus Resection for Stage 1 A Renal Cell Carcinoma: National Variation in Clinical Management and Selected Outcomes. Radiology. 2018;288(3):889-97. Go to original source... Go to PubMed...
  20. Yu J, Zhang G, Liang P, et al. Midterm results of percutaneous microwave ablation under ultrasound guidance versus retroperitoneal laparoscopic radial nephrectomy for small renal cell carcinoma. Abdom Imaging. 2015;40(8): 3248-56. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.